FDA Approves Innovative At-Home Device for Depression Treatment

In a significant advancement in mental health, the United States Food and Drug Administration (FDA) has approved the first device for at-home brain stimulation to combat depression. Developed by Flow Neuroscience, this innovative tool presents a promising alternative for millions seeking relief from traditional antidepressant medications.

Depression has increasingly become a pressing health issue nationwide. The Centers for Disease Control and Prevention (CDC) reports that the prevalence of depression has surged by nearly 60% in the last decade, with over 20 million adults in the U.S. currently affected. Many individuals rely on long-term medication that often comes with undesirable side effects, prompting a search for more effective and non-invasive treatment options.

Named FL-100, Flow Neuroscience’s device introduces a fresh method of treatment. It employs a gentle electrical current to stimulate the brain region linked to mood regulation. This technique, known as transcranial direct current stimulation (tDCS), has been the focus of research for years. The uniqueness of the FL-100 lies in its home use capability, allowing patients to receive therapy under the supervision of healthcare providers without needing to leave their homes.

The FDA has approved the device for individuals aged 18 and above who are experiencing moderate to severe major depressive disorder. It can be utilized on its own or in conjunction with therapy or medication, but it is not suitable for those whose depression is resistant to conventional treatments.

Flow intends to launch the FL-100 in the U.S. market in the second quarter of 2026, requiring a prescription. The expected price ranges from $500 to $800. Erin Lee, the CEO of Flow, indicated that the company is already negotiating with insurance providers for coverage, and more information will be available in early 2026. If insurance companies opt to cover the device, it may significantly ease the financial burden for many patients.

This device is not a novel introduction to the world; over 55,000 users in Europe, the UK, Switzerland, and Hong Kong have already benefited from it. Its FDA approval was supported by a thorough clinical study, revealing that 58% of participants achieved remission after just 10 weeks, even if they were already on medication or therapy. Moreover, Flow reported that 77% of global users experienced improvements within three weeks.

The treatment regimen lasts 12 weeks, with users employing the device five times a week for the first three weeks, followed by two or three sessions per week for the remaining nine weeks. Each session spans approximately 30 minutes, allowing for seamless integration into daily activities.

Flow asserts that the device is generally safe, with most side effects being mild and temporary. These may include minor skin irritations, headaches, or tingling sensations where the pads are applied. However, the company cautions about the potential for skin burns if pads are reused or become too dry, emphasizing the need for strict adherence to instructions for safe use.

The approval of the FL-100 represents a pivotal step in enhancing mental health care across the U.S. While traditional antidepressants and therapy remain critical, this new device introduces an additional, medication-free option—advancing treatment accessibility and reducing stigma surrounding depression.

As depression rates continue to rise, emerging solutions like the FL-100 showcase the synergy of science and technology in transforming lives. If successful in the U.S. market, this device could become an integral part of depression care, offering renewed hope to many seeking relief.